- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MNMD
Recent news which mentions MNMD
Fintech Focus For December 13, 2021
December 12, 2021
From Benzinga
From Benzinga
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
From Benzinga
FDA Shows Support For Development Of MindMed's Session Monitoring System
December 09, 2021
Tickers
MNMD
From Benzinga
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
December 08, 2021
From Benzinga
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
December 01, 2021
Tickers
MNMD
From InvestorPlace
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
November 30, 2021
Tickers
MNMD
From Benzinga
3 Psychedelic Stocks for Potential Out-of-This-World Gains
November 18, 2021
From InvestorPlace
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
November 16, 2021
Tickers
MNMD
From Benzinga
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
November 11, 2021
From Benzinga
From InvestorPlace
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
November 02, 2021
From Benzinga
From Benzinga
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
November 01, 2021
From Benzinga
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
October 27, 2021
From Benzinga
These 4 Psychedelic Biotech Stocks Are Leading the Pack
October 26, 2021
From Motley Fool
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
October 20, 2021
From Benzinga
7 Penny Stocks to Buy – While They’re Still Penny Stocks
October 19, 2021
From InvestorPlace
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
From Benzinga
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
October 18, 2021
From InvestorPlace
From Benzinga
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
October 11, 2021
From Benzinga
Former Tilray CEO Joins Psychedelics Company
October 07, 2021
From Benzinga
7 Penny Stocks to Pick Up if You Have $100 to Spare
October 07, 2021
From InvestorPlace
MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression
October 05, 2021
Tickers
MNMD
From Benzinga
From Benzinga
From Benzinga
6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments?
October 01, 2021
From Benzinga
Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference
September 30, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.